Dr. Diaz on Response Rates With Pembrolizumab for CRC

Luis A. Diaz, MD
Published: Wednesday, Aug 02, 2017



Luis A. Diaz, MD, head of the division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses the response rates of pembrolizumab (Keytruda) for patients with colorectal cancer (CRC).

The KEYNOTE-177 trial demonstrates that, in CRC and non-CRC, response rates with pembrolizumab are quite impressive. The progression-free survival and overall survival are quite durable, and it's recapitulated in entirely different studies, explains Diaz.

According to Diaz, what's impressive about the FDA approval is that it is not only across all tumor types, but it is in adults and children. This FDA approval has the potential to knock down the walls of how we think about cancer in the future, states Diaz.



Luis A. Diaz, MD, head of the division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses the response rates of pembrolizumab (Keytruda) for patients with colorectal cancer (CRC).

The KEYNOTE-177 trial demonstrates that, in CRC and non-CRC, response rates with pembrolizumab are quite impressive. The progression-free survival and overall survival are quite durable, and it's recapitulated in entirely different studies, explains Diaz.

According to Diaz, what's impressive about the FDA approval is that it is not only across all tumor types, but it is in adults and children. This FDA approval has the potential to knock down the walls of how we think about cancer in the future, states Diaz.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x